We then tested our model within a clinical setting to explain VEGF changes in patients with cancer who experience different treatment outcomes; we found that our predictions were consistent with the observed VEGF changes in patients receiving sunitinib for the treatment of metastatic renal cancer (Kontovinis et al., 2009). Here, VEGFA is linked to cancer.